Is FDG-PET/CT Useful for Diagnosing Pulmonary Metastasis in Patients with Soft Tissue Sarcoma?

Hagi, Tomohito; Nakamura, Tomoki; Sugino, Yusuke; Matsubara, Takehiro; Asanuma, Kunihiro; Sudo, Akihiro

doi:10.21873/anticanres.12638

Cited by 12 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of the present study ratify the ability of PET/CT to identify a higher number of metastases if compared to CT scans, particularly regarding bone lesions for which only half of FDG-avid lesions had a corresponding osteostructural alteration on CT images. Concerning lung metastases, results confirmed the high positive predictive value of FDG uptake in metastatic pulmonary nodules, but also the low sensitivity in evaluating small metastases [21]. In detail, the results of this series suggest a high reliability of PET/CT in the characterization of nodules greater than eight millimeters, while those of 6-8 mm could cautiously be considered metastatic, particularly if the T/B ratios are close to the cut off value of 1.2.…”

Section: Discussionsupporting

confidence: 64%

Diagnostic and Clinical Impact of 18F-FDG PET/CT in Staging and Restaging Soft-Tissue Sarcomas of the Extremities and Trunk: Mono-Institutional Retrospective Study of a Sarcoma Referral Center

Annovazzi

Rea

Zoccali

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Soft-tissue sarcomas (STS) represent a wide heterogeneous class of rare tumors. The exact role 18F-fluorodeoxyglucose positron emission/computed tomography (18F-FDG PET/CT) in the evaluation of STS is not well established. The aim of the present study was to evaluate how the use of 18F-FDG PET/CT in STS could influence patient therapy planning, looking for a possible added value over computed tomography and magnetic resonance imaging—the most used modalities in the study of STS. Differences in SUVmax according to histologic subtype and tumor grade were also considered. Methods: a total of 345 consecutive 18F-FDG PET/CT scans performed for initial staging (n = 171) or for suspected disease relapse (n = 174) in 282 patients with STS extracted from the local Information System database were retrospectively reviewed. Results: 18F-FDG PET/CT altered therapy planning in 80 cases (16.4% for staging and 29.9% in restaging), both for disease upstaging (58.8%) and downstaging (41.2%) Conclusions: 18F-FDG PET/CT could significantly influence management of patients with STS, particularly for restaging.

show abstract

Section: Discussionsupporting

confidence: 64%

Diagnostic and Clinical Impact of 18F-FDG PET/CT in Staging and Restaging Soft-Tissue Sarcomas of the Extremities and Trunk: Mono-Institutional Retrospective Study of a Sarcoma Referral Center

Annovazzi

Rea

Zoccali

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…SUVmax is the most widely used parameter to measure the uptake of a radiolabeled tracer by tumor tissue [29]. In this study, the median SUVmax in STM was 6.12 (range 0.8-20.9); while that in skeletal muscle and subcutaneous metastases was 6.79 (range 2.1-20.9) and 5.36 (range 0.8-19.1),…”

Section: Survival Timementioning

confidence: 69%

18F-FDG PET/CT is Valuable in Detecting Soft-tissue Metastasis of Lung Cancer

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Soft-tissue metastasis (STM) is a relatively rare, but not exceptional, manifestation of lung cancer. Since the lesions of STM are usually asymptomatic, they are easy to miss during clinical evaluation. The aim of the study was to explore the incidence and characteristics of STM in lung cancer using fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT), and evaluate its effect on tumor staging and treatment. Methods We analyzed 4543 patients with lung cancer who underwent 18 F-FDG PET/CT in our hospital between January 2013 and September 2018. 85 were diagnosed with STM and included in the study group. Imaging characteristics, clinical symptoms, and survival time (from confirmed STM to death) were recorded for all study subjects. Results A total of 219 lesions were identified by 18 F-FDG PET/CT: 215 were detected by PET (maximum standardized uptake value = 6.12); 139 were detected by CT. Muscle STM were primarily found in the hip, upper limb muscle; whereas subcutaneous STM were mainly distributed in the chest and abdomen, back. In 68 patients (80%), STM were found incidentally during routine 18 F-FDG PET/CT staging. The lesions were symptomatic in 17 cases (20%); in 10 patients (11.8%) STM was the first manifestation. Other site metastases were detected in 79 patients (92.9%). Isolated STM were found in 6 patients (7.1%), whose tumor staging and treatment were affected by PET/CT findings. At the end of the follow-up period, 69 patients were dead (median survival time= 5.0 months) and 5 were lost to follow-up. Conclusions STM may be a sign of advanced stage and poor prognosis in lung cancer. 18 F-FDG PET/CT is highly valuable in the detection of STM, and can impact tumor staging and management of lung malignancies.

show abstract

“…SUVmax is the most widely used parameter to measure the uptake of a radiolabeled tracer by tumor tissue [34]. In this study, the median SUVmax of STM was 6.12 (range 0.8-20.9) while that of skeletal muscle and subcutaneous metastases was 6.79 (range 2.1-20.9) and 5.36 (range 0.8-19.1), respectively.…”

Section: Overall 1- 3- and 5-year Survival Rates In The Stm And Nonmentioning

confidence: 70%

Imaging features and prognostic value of 18F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study

Zhang

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: Soft-tissue metastasis (STM) is a relatively rare, but not exceptional, manifestation of lung cancer. The purpose of this study was to evaluate the imaging features of STM from lung cancer using fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT), and assess the impact of STM detected at baseline PET/CT on patient survival. Methods: Out of 4543 patients with lung cancer who underwent 18 F-FDG PET/CT in our hospital between January 2013 and September 2018, 85 were diagnosed with STM (78 at baseline PET/CT and 7 at restaging PET/CT) and included in the imaging study. We conducted a comparative survival analysis between patients with stage 4 lung cancer with and without STM at baseline PET/CT (n = 78 in each group) and performed univariate and multivariate analyses to investigate the factors affecting the prognosis of lung cancer. Results: A total of 219 lesions were identified by 18 F-FDG PET/CT: 215 were detected by PET and 139 by CT. Muscle STM were primarily found in the hip and upper limb muscle, whereas subcutaneous STM were mainly distributed in the chest, abdomen, and back. In 68 patients, STM were found incidentally during routine 18 F-FDG PET/CT staging. Isolated STM were detected in 6 patients, whose tumor staging and treatment were affected by PET/CT findings. There were no significant differences in the 1-, 3-, and 5-year survival rates between patients with and without STM at baseline PET/CT. Brain and adrenal metastases, but not STM, were associated with poor prognosis of stage 4 lung cancer.

show abstract

Is FDG-PET/CT Useful for Diagnosing Pulmonary Metastasis in Patients with Soft Tissue Sarcoma?

Cited by 12 publications

References 14 publications

Diagnostic and Clinical Impact of 18F-FDG PET/CT in Staging and Restaging Soft-Tissue Sarcomas of the Extremities and Trunk: Mono-Institutional Retrospective Study of a Sarcoma Referral Center

Diagnostic and Clinical Impact of 18F-FDG PET/CT in Staging and Restaging Soft-Tissue Sarcomas of the Extremities and Trunk: Mono-Institutional Retrospective Study of a Sarcoma Referral Center

18F-FDG PET/CT is Valuable in Detecting Soft-tissue Metastasis of Lung Cancer

Imaging features and prognostic value of 18F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study

Contact Info

Product

Resources

About